Does St John's wort work for depression?

For decades it was assumed that hypericin — the reddish pigment that gives the plant its name — was the active antidepressant compound. Research over the last 25 years has shifted this understanding to hyperforin, another constituent found in the resinous glands of the flowers and leaves.

Hyperforin inhibits the reuptake of serotonin, dopamine, norepinephrine, GABA, and L-glutamate simultaneously². This is mechanistically different from SSRIs, which selectively block the serotonin transporter. Hyperforin achieves reuptake inhibition not by blocking transporters directly, but by elevating free intracellular sodium concentration — a novel mechanism that explains why the herb has a broader spectrum of action than most pharmaceutical antidepressants.

The clinical significance of hyperforin content is now well-established. Extracts standardized to 3-5% hyperforin consistently outperform those with low or no hyperforin in clinical trials. This makes extract quality critical: cheap, unstandardized products may have little active compound.

What the Trials Show

The most comprehensive analysis of the evidence — a 2005 meta-analysis of 37 double-blind randomized trials — found that St. John's Wort monopreparations were significantly superior to placebo (relative risk 1.28-1.87) and statistically equivalent to standard antidepressants (relative risk 1.00-1.02) across trials targeting mild to moderate depression¹. Side effects were consistently lower than for both tricyclic antidepressants and SSRIs.

A major U.S. trial published in JAMA in 2002 tested St. John's Wort against sertraline (Zoloft) and placebo in 340 adults with moderately severe major depression³. Neither St. John's Wort nor sertraline outperformed placebo on the primary outcome — a reminder that even pharmacological antidepressants often struggle against placebo in severe depression, and that the herb may have limited efficacy outside the mild-to-moderate range.

The practical takeaway: St. John's Wort appears most effective for mild to moderate depression, which is where most people first look for help. It is not well-supported for severe depression or depression with psychotic features.

Dosage and Extract Quality

Standard clinical dosing is 300 mg three times daily (900 mg total) of an extract standardized to 0.3% hypericin and 3-5% hyperforin. Most of the positive trials used WS 5570 (Perika) or ZE 117 (Remotiv) extracts, both of which are standardized products with consistent hyperforin content.

Onset is typically 4 to 6 weeks — similar to pharmaceutical antidepressants. Don't judge effectiveness before 6 weeks of consistent use.

Drug Interactions: The Critical Warning

St. John's Wort is a potent inducer of CYP3A4, a liver enzyme responsible for metabolizing roughly half of all pharmaceutical drugs⁴. A 14-day course of standard-dose St. John's Wort significantly increases CYP3A4 activity, reducing blood levels of drugs that depend on this pathway.

Medications with clinically significant interactions include:

• Oral contraceptives — reduced effectiveness; unintended pregnancies have been reported
• HIV antiretrovirals (particularly protease inhibitors and NNRTIs)
• Immunosuppressants (cyclosporine, tacrolimus) — organ rejection risk in transplant patients
• Warfarin and anticoagulants
• Digoxin
• Some chemotherapy agents

St. John's Wort also carries a risk of serotonin syndrome if combined with SSRIs, SNRIs, tramadol, or other serotonergic drugs. This combination should be avoided entirely.

Anyone taking prescription medications should consult a pharmacist or physician before using St. John's Wort.

Light Sensitivity

Hypericin can cause photosensitivity — increased sensitivity of the skin to ultraviolet light — particularly at high doses. Fair-skinned individuals and those with significant sun exposure should be aware of this risk, though it is rare at standard therapeutic doses.

See our Ashwagandha page for another well-studied adaptogen approach to stress and mood.

Meta-Analytic Evidence

The 2005 meta-analysis by Linde et al. synthesized 37 double-blind randomized controlled trials enrolling a combined several thousand patients¹. Trials compared Hypericum monopreparations to placebo (26 trials) or standard antidepressants (14 trials). The pooled response rate versus placebo showed a relative risk of 1.28 to 1.87 depending on diagnostic criteria and outcome measures used.

The comparison to antidepressants showed equivalence (RR 1.00-1.02) with a consistently more favorable side-effect profile. Dropout rates due to adverse events were significantly lower for St. John's Wort across all comparative trials. The authors noted significant heterogeneity across studies, primarily attributed to differences in extract quality, standardization, and patient populations — reinforcing that extract quality is a meaningful variable.

The JAMA Severity Ceiling

The Hypericum Depression Trial Study Group (2002) enrolled 340 adults meeting DSM-IV criteria for major depression at the moderately severe level (Hamilton Depression Rating Scale score ≥20)³. Participants were randomized to H. perforatum 900-1500 mg/day, sertraline 50-100 mg/day, or placebo for 8 weeks.

Full response rates: H. perforatum 14.3%, sertraline 24.8%, placebo 31.9%. Neither active treatment significantly outperformed placebo on the primary HAMD-17 outcome. On the secondary Clinical Global Impression scale, sertraline did outperform placebo, while H. perforatum did not.

This trial is frequently cited as evidence that St. John's Wort doesn't work — but a more accurate interpretation is that it highlights a severity ceiling: the herb performs better in mild-to-moderate depression, while severe depression (HAMD ≥20) may require more aggressive intervention. Notably, sertraline also failed the primary endpoint, illustrating how difficult severe depression is to treat in RCT conditions.

Mechanism: Hyperforin's Sodium Transporter Model

Singer et al. (1999) established that hyperforin's mechanism differs fundamentally from classical reuptake inhibitors². Rather than blocking transporter proteins directly, hyperforin activates sodium-conductive ion channels, raising intracellular sodium concentrations. This elevated sodium reduces the electrochemical gradient driving neurotransmitter uptake, effectively slowing reuptake of serotonin, dopamine, norepinephrine, GABA, and L-glutamate simultaneously.

This pan-reuptake inhibition — across five neurotransmitter systems — may partly explain why St. John's Wort has shown activity in conditions beyond depression, including anxiety, seasonal affective disorder, and premenstrual syndrome in smaller studies. It also means the receptor profile and downstream effects differ from SSRIs, which may be relevant for patients who respond poorly to serotonin-selective agents.

Extracts with reduced hyperforin content (<1%) have shown consistently weaker antidepressant effects in clinical trials, confirming hyperforin as the principal bioactive constituent for mood effects.

CYP3A4 Induction: Pharmacokinetic Evidence

Roby et al. (2000) directly measured CYP3A4 activity in 13 healthy volunteers before and after 14 days of St. John's Wort (300 mg three times daily, 0.3% hypericin)⁴. CYP3A4 activity was quantified via urinary 6-beta-hydroxycortisol to cortisol ratio — a validated endogenous marker of CYP3A4 induction.

After 14 days, the ratio increased significantly, confirming robust CYP3A4 induction at standard therapeutic doses. The authors flagged implications for drug-herb interactions across all CYP3A4-substrate medications.

Subsequent pharmacokinetic studies confirmed that plasma concentrations of cyclosporine, indinavir, digoxin, warfarin, and oral contraceptive hormones are all reduced 30-50% or more by concurrent St. John's Wort use. These are clinically consequential reductions that have caused documented treatment failures and adverse events in transplant, HIV, and anticoagulation patients.

Evidence Strength Assessment

• Mild-to-moderate depression: Strong — supported by multiple RCTs and meta-analyses showing superiority to placebo and equivalence to SSRIs
• Severe depression: Weak — limited by the JAMA 2002 findings; not recommended
• Mechanism of action: Strong — hyperforin's sodium-channel model is well-characterized
• Drug interactions (CYP3A4): Strong — direct pharmacokinetic evidence; clinical consequences documented
• Anxiety, SAD, PMS: Preliminary — some positive signals in smaller trials, insufficient for firm conclusions

St. John's Wort is one of the best-evidenced herbal medicines available and deserves serious clinical consideration for mild to moderate depression — with equal seriousness given to its interaction profile before prescribing or recommending it alongside other medications.